Other
MPR
0
Pipeline Programs↗
14
Active Trials↗
11
Companies Involved↗
MPR is an early-stage landscape with 0 programs across 11 companies. The most active players are GSK, Pfizer, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
98
clinical trials
Completed68 · 69%
Unknown status9 · 9%
Active, not recruiting5 · 5%
Recruiting5 · 5%
Terminated4 · 4%
Enrolling by invitation3 · 3%
Other4 · 4%
Clinical Trials
Trial Activity
98 trials
Improving Physical Ability and Cellular Senescence Elimination in HIV
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07144293·82 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)